Archiv
Archiv anzeigen:
bis


Factors Influencing Hemoglobin Increments After Transfusion

Brady L. Stein, MD, MHS reviewing Roubinian NH et al. Blood 2019 Sep 26

Transfusion efficacy was influenced by gender, donor age, irradiation, apheresis collection, storage duration, and Rh-D positivity.


MYC Rearrangement and Prognosis in Diffuse Large B-Cell Lymphoma

Michael E. Williams, MD, ScM reviewing Rosenwald A et al. J Clin Oncol 2019 Sep 9

Isolated MYC gene rearrangement had minimal negative prognostic impact compared with double- or triple-hit lymphoma.


Drug Sequencing in Metastatic Castration-Resistant Prostate Cancer

Robert Dreicer, MD, MS, MACP, FASCO reviewing de Wit R et al. N Engl J Med 2019 Sep 30

In patients with disease progression after first androgen-deprivation therapy, survival was longer with cabazitaxel than with abiraterone or enzalutamide.


EGFR-Inhibitor Therapy for non-V600E BRAF-Mutant Colorectal Cancer

David H. Ilson, MD, PhD reviewing Yaeger R et al. Clin Cancer Res 2019 Sep 12

Patients with class 3 BRAF mutations might benefit from anti-EGFR therapy; those with class 2 mutations are unlikely to respond.


Microsatellite Instability: A Biomarker in Gastric Cancer

David H. Ilson, MD, PhD reviewing Pietrantonio F et al. J Clin Oncol 2019 Sep 12

Survival was superior in patients with microsatellite instability versus microsatellite stability.


Insights into Male Breast Cancer

William J. Gradishar, MD reviewing Wang F et al. JAMA Oncol 2019 Sep 19

Overall survival was significantly worse for men with breast cancer than for their women counterparts.


Pegylated Interferon for Essential Thrombocythemia and Polycythemia Vera

Brady L. Stein, MD, MHS reviewing Yacoub A et al. Blood 2019 Sep 12

High overall response rates were noted in high-risk patients with prior hydroxyurea resistance or intolerance.


Proton-Beam Radiation Therapy for Breast Cancer

William J. Gradishar, MD reviewing Jimenez RB et al. J Clin Oncol 2019 Aug 26

PBRT successfully spared cardiac and lung tissues while delivering a homogenous dose to the target tissue.


When to Restart Anticoagulation After a Gastrointestinal Bleed

Kenneth R. DeVault, MD reviewing Sostres C et al. Aliment Pharmacol Ther 2019 Sep 4

Early resumption of anticoagulation is essential to reduce the risk for vascular events and death.


Archiv
Seite von 84
Editorial Member Board Empfehlungen

Prof. Dr. med. Christoph Rochlitz

Chefarzt Onkologie
Universitätsspital Basel

E-Mail: E-Mail anzeigen

Liebe Kolleginnen und Kollegen!

In der vorliegenden Ausgabe von NEJM Journal Watch möchte ich Ihnen gerne wieder einige rezent publizierte Studien aus dem Bereich Onkologie/Hämatologie näherbringen.

Kommentar weiterlesen

Do CDK4/6 Inhibitors Improve Overall Survival in Advanced Breast Cancer?

William J. Gradishar, MD reviewing Turner NC et al. N Engl J Med 2018 Oct 20

Overall survival trended longer with the addition of palbociclib to endocrine therapy in patients with ER-positive/HER2-negative metastatic disease.


Immunotherapy for Breast Cancer Has Arrived

William J. Gradishar, MD reviewing Schmid P et al. N Engl J Med 2018 Oct 20

Adding atezolizumab to nab-paclitaxel prolonged progression-free survival in patients with metastatic triple-negative breast cancer.


Brigatinib for ALK-Positive, Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Camidge DR et al. N Engl J Med 2018 Sep 25

Progression-free survival was prolonged with front-line brigatinib versus crizotinib.


Front-Line Therapy for Extensive-Stage, Small Cell Lung Cancer: A New Standard

Anne S. Tsao, MD reviewing Horn L et al. N Engl J Med 2018 Sep 25

Adding atezolizumab to chemotherapy significantly improved overall and progression-free survival.


A New Standard of Care for Squamous Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Paz-Ares L et al. N Engl J Med 2018 Sep 25

Adding the PD-1 inhibitor pembrolizumab to carboplatin-taxane chemotherapy significantly improved response and survival.


Durvalumab After Chemoradiation for Advanced Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Antonia SJ et al. N Engl J Med 2018 Sep 25

Two-year overall survival was significantly improved with durvalumab versus placebo.


Omission of Axillary Dissection for Minimal Node-Positive Breast Cancer

William J. Gradishar, MD reviewing Galimberti V et al. Lancet Oncol 2018 Sep 5

Long-term follow-up data confirm that axillary dissection is unnecessary in patients with minimal tumor burden in the sentinel nodes.


Olaparib plus Abiraterone for Advanced Prostate Cancer

Robert Dreicer, MD, MS, MACP, FASCO reviewing Clarke N et al. Lancet Oncol 2018 Jul

Progression-free survival was significantly longer with olaparib than with placebo.


Combination Immunotherapy for Metastatic Melanoma with Brain Metastases

Sunandana Chandra, MD, MS reviewing Tawbi HA et al. N Engl J Med 2018 Aug 23, Turajlic S and Larkin J. N Engl J Med 2018 Aug 23

Ipilimumab plus nivolumab proved safe and efficacious in a phase II trial.


First-Line Lenvatinib vs. Sorafenib for Unresectable Hepatocellular Carcinoma

David H. Ilson, MD, PhD reviewing Kudo M et al. Lancet 2018 Feb 9, Reig M and Bruix J. Lancet 2018 Feb 9

Overall survival was noninferior and progression-free survival and response were superior with lenvatinib.